Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520
Debt
Debt-to-Equity RatioN/A
Current Ratio13.76
Quick Ratio13.76
Price-To-Earnings
Trailing P/E Ratio-3.50
Forward P/E Ratio-4.81
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.03 per share
Price / Book2.36
Profitability
EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-45.65%
Return on Assets-41.62%
Miscellaneous
Employees55
Outstanding Shares29,200,000
Market Cap$273.58 million
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) issued its earnings results on Thursday, August, 2nd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.25. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 analysts have issued twelve-month target prices for Corvus Pharmaceuticals' shares. Their predictions range from $15.00 to $17.00. On average, they expect Corvus Pharmaceuticals' stock price to reach $16.00 in the next year. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Apellis Pharmaceuticals (APLS), Radius Health (RDUS), Assembly Biosciences (ASMB), TG Therapeutics Inc common stock (TGTX), Revance Therapeutics (RVNC), Tricida (TCDA), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Amarin (AMRN) and Dynavax Technologies (DVAX).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 67)
- Mr. Leiv Lea, Chief Financial Officer (Age 64)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 56)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 51)
- Mr. Alan C. Mendelson Esq., Sec.
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
Media coverage about CRVS stock has trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned headlines about the company an impact score of 46.87 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Corvus Pharmaceuticals.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (8.49%), BlackRock Inc. (3.83%), Cowen Inc. (1.83%), Millennium Management LLC (1.18%), Renaissance Technologies LLC (1.11%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which major investors are selling Corvus Pharmaceuticals stock?
Which major investors are buying Corvus Pharmaceuticals stock?
CRVS stock was purchased by a variety of institutional investors in the last quarter, including Cowen Inc., BlackRock Inc., International Biotechnology Trust PLC, Dimensional Fund Advisors LP, Rhumbline Advisers, Acadian Asset Management LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $9.53.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $273.58 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
